In the benchmark T47D ER+HER2− breast cancer CDX model, fulvestrant monotherapy provided a moderate level of tumor growth control, whereas low-dose STX-478 monotherapy and high-dose alpelisib resulted in tumor stasis. Here, ERBB2 is linked to breast cancer.